| 1 |
中国门静脉高压诊断与监测研究组(CHESS)，中华医学会消化病学分会微创介入协作组，中国医师协会介入医师分会急诊介入专业委员会．中国肝静脉压力梯度临床应用专家共识(2018版)[J]．中华消化杂志，2018，38(11):728.
|
| 2 |
彭颖，祁兴顺，郭晓钟.2015年BavenoⅥ共识：门静脉高压的风险分层及个体化管理[J]．临床肝胆病杂志，2015(8):1202-1207.
|
| 3 |
徐小元，丁惠国，李文刚，等．肝硬化诊治指南[J]．临床肝胆病杂志，2019，35(11):2408-2407.
|
| 4 |
张静，陈明锴．门脉高压症的诊断与治疗进展[J]．胃肠病学和肝病学杂志，2018(3):341-345.
|
| 5 |
王建荣，陆文霞，夏玉敬，等．门脉高压药物治疗进展[J]．世界临床药物，2016，289(1):70-75.
|
| 6 |
中国医师协会急诊医师分会．急性上消化道出血急诊诊治流程专家共识[J]．中国急救医学，2015(35):873.
|
| 7 |
D′Amico G, Pagliaro L, Bosch J．Pharmacological Treatment of Portal Hypertension：An Evidence-Based Approach[J]．Semin Liver Dise，1999，19(4):475-505.
|
| 8 |
Osterman M．A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding[J]．Yearbook of Gastroenterology，2007，2007:167-168.
|
| 9 |
Bosch J, Juan Carlos García-Pagán.Complications of cirrhosis.I.Portal Hypertension[J]．J Hepatol，2000，32(1 Suppl):141-156.
|
| 10 |
中华医学会肝病学分会，中华医学会消化病学分会，中华医学会消化内镜学分会．肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]．中华内科杂志，2016，55(1):57-72.
|
| 11 |
周光文，杨连粤．肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2015)[J]．中国实用外科杂志，2015(10):1086-1090.
|
| 12 |
Sharma M, Singh S, Desai V，et al.Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding：A Systematic Review and Network Meta-analysis[J]．Hepatology，2019，69(4):1657-1675.
|
| 13 |
Garcia-Tsao G, Abraldes J G, Berzigotti A，et al.Portal Hypertensive Bleeding in Cirrhosis：Risk Stratification，Diagnosis and Management-2016 Practice Guidance by the American Association for the Study of Liver Diseases[J]．Hepatology，2016，65(1):310-335.
|
| 14 |
Garcia-Tsao G, Bosch J．Management of varices and variceal hemorrhage in cirrhosis[J]．N Engl J Med，2010，362(9):823-832.
|
| 15 |
Reiberger T, Ulbrich G, Ferlitsch A，et al.Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]．Gut，2013，62(11):1634-1641.
|
| 16 |
Gupta V, Rawat R, Shalimar，et al.Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed：RCT[J]．Hepatol Int，2017，11(2):181-187.
|
| 17 |
Abid S, Ali S, Baig M A，et al.Is it time to replace propranolol with carvedilol for portal hypertension？[J]．World J Gastrointest Endosc，2015，7(5):532-539.
|
| 18 |
Sánchez del Monte J, Ramos Gómez MV, Velazquez Ochoa E．Comparative study of propranolol versus propranolol plus isosorbide 5-mononitrate in portal hypertension in cirrhotics.Evaluating splanchnic hemodynamics with color Doppler ultrasound[J]．Rev Gastroenterol Mex，2005，70(3):261-268.
|
| 19 |
Kamath, Patrick S．Esophageal variceal bleeding：Primary prophylaxis[J]．Clin Gastroenterol Hepatol，2005，3(1):90-93.
|
| 20 |
侯辉，程云生．门脉高压症的综合治疗进展[J]．医学综述，2010，16(13):2027-2029.
|
| 21 |
Tandon P, Abraldes JG, Berzigotti A，et al.Renin-angiotensinaldosterone inhibitors in the reduction of portal pressure：a systematic review and meta-analysis[J]．J Hepatol，2010，53(2):273-282.
|
| 22 |
Park D H, Baik S K, Choi Y H，et al.Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats[J]．Korean J Hepatol，2007，13(1):61-69.
|
| 23 |
Kim JH, Kim JM, Cho YZ，et al.Effects of candesartan and pro-pranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.Clin Mol Hepatol，2014，20(4):376-383.
|
| 24 |
Zafra C, Abraldes JG, Turnes J，et al.Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis[J]．Gastroenterology，2004，126(3):749-755.
|
| 25 |
Harnois DM.Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension：A Randomized Controlled Trial[J]．Yearbook of Medicine，2010，2010:468-469.
|
| 26 |
Abraldes JG, Villanueva C, Aracil C，et al.Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis.Gastroenterology，2016，150(5):1160-1170.e3.
|
| 27 |
Aina Rodríguez-Vilarrupla, Bàrbara Lavina, Héctor García-Calderó，et al.PPARαactivation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats[J]．J Hepatol，2012，56(5):0-1039.
|
| 28 |
Mejias M, Ester Garcia-Pras, Tiani C，et al.Beneficial effects of sorafenib on splanchnic，intrahepatic，and portocollateral circulations in portal hypertensive and cirrhotic rats[J]．Hepatology，2009，49(4):1245-1256.
|
| 29 |
朱云，李爱民，罗荣城．索拉非尼对门静脉高压症的治疗作用及其机制[J]．南方医科大学学报，2014(1):133-136.
|
| 30 |
D′Amico M, Mejías M, García-Pras E，et al.Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats[J]．AJP Gastroint Liver Physiol，2012，302(10):G1191-1198.
|
| 31 |
Dong T, Aronsohn A, Reddy K G，et al.Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis[J]．Dig Dis Sci，2016，61(12):1-6.
|
| 32 |
吕新月，李磊．利福昔明在肝硬化相关并发症中的应用[J]．临床肝胆病杂志，2018，34(7):190-193.
|